Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 15/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606829 | 0.93 | TLR4 (0.49) | TLR4CNR2 | |
| SCHEMBL8521122 | 0.88 | TLR4 (0.49) | TLR4CNR2LY96 | |
| SCHEMBL8431613 | 0.87 | TLR4 (0.54) | TLR4LY96 | |
| SCHEMBL9749817 | 0.86 | TLR4 (0.46) | TLR4 | |
| SCHEMBL8520484 | 0.86 | TLR4 (0.47) | TLR4TLR2 | |
| SCHEMBL8520550 | 0.83 | TLR4 (0.45) | TLR4CNR2KMT2A | |
| SCHEMBL6911473 | 0.81 | TLR4 (0.43) | TLR4LY96 | |
| SCHEMBL6800817 | 0.80 | TLR4 (0.54) | TLR4LY96 | |
| SCHEMBL8520813 | 0.80 | TLR4 (0.37) | TLR4CNR2MEN1KMT2A | |
| SCHEMBL8521582 | 0.80 | TLR4 (0.55) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0226381-B1 | NOVEL GLUCOPYRANOSE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-02-05 | — | — | EP | claimed |
| EP-0226381-A2 | Novel glucopyranose derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1987-06-24 | — | — | EP | claimed |
| US-4925929-A | ANTITUMOR AGENTS | ONO PHARMACEUTICAL CO. LTD. (JP) | 1990-05-15 | — | — | US | disclosed |